Fig. 1: Outcomes after CARCIK-CD19 infusion. | Blood Cancer Journal

Fig. 1: Outcomes after CARCIK-CD19 infusion.

From: Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation

Fig. 1

A OS, and EFS, in the 36 patients who received CARCIK-CD19 at the recommended dose. Kaplan–Meier estimates of OS and EFS. EFS was estimated censoring at treatment shift and all estimates are reported with the corresponding SE. B DOR in the 30 patients who received CARCIK-CD19 and achieved CR. Kaplan–Meier estimates of DOR. DOR was estimated censoring at treatment shift and all estimates are reported with the corresponding SE. C OS among 34 patients who received CARCIK-CD19 according to number of prior alloHSCT and bone marrow burden post-lymphodepletion.

Back to article page